72 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
7 May 24
Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
7:10am
within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters
8-K
EX-10.1
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
.
(h) Litigation. There is no action, suit, proceeding or investigation pending or, to the Knowledge of the Company, threatened (including “cease … shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party
8-K
RYTM
Rhythm Pharmaceuticals Inc.
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained
8-K
EX-99.1
adp4c 66xskcs555m
1 Apr 24
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
5:25pm
8-K
EX-99.1
y20q5h6so
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
8-K
z4b5ykvv7wvy
4 Jan 24
Entry into a Material Definitive Agreement
7:00am
8-K
f456lo7a30x36gwn0jsj
6 Dec 23
Other Events
4:30pm
8-K
EX-99.1
tswo1 jafzziu
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
8-K
z4vi7s 6q
21 Aug 23
Other Events
4:30pm
8-K
EX-99.1
4l7blam
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
pb67iisd0wm4b0k
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am